We are live on ! Find out more
TLP

Tri Locum Partners Portfolio holdings

AUM $713M
1-Year Est. Return 68.92%
This Fund
S&P 500
This Quarter Est. Return
+19.03%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$417M
AUM Growth
+$21.9M
Cap. Flow
-$16.8M
Cap. Flow %
-4.02%
Top 10 Hldgs %
79.89%
Holding
27
New
2
Increased
11
Reduced
6
Closed
7

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$33.1M
2
STVN icon
Stevanato
STVN
+$26.2M
3
VRNA
Verona Pharma
VRNA
+$14.6M
4
PCVX icon
Vaxcyte
PCVX
+$14.3M
5
NTRA icon
Natera
NTRA
+$9.97M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$31.1M
2
AMGN icon
Amgen
AMGN
+$25.7M
3
AXSM icon
Axsome Therapeutics
AXSM
+$18.7M
4
REGN icon
Regeneron Pharmaceuticals
REGN
+$18.4M
5
INSM icon
Insmed
INSM
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REGN icon
26
Regeneron Pharmaceuticals
REGN
$78.3B
– –
-17,516
Closed -$18.4M
XENE icon
27
Xenon Pharmaceuticals
XENE
$6.19B
– –
-101,959
Closed -$3.98M
1
2

Similar funds

DCM
Defilade Capital Management Emeryville, California $712M AUM
AMPWP
Alvarez & Marsal Private Wealth Partners West Palm Beach, Florida $712M AUM
DCM
Dimension Capital Management Coral Gables, Florida $713M AUM 18.57% 1-Year Est. Return
IWP
Insight Wealth Partners Plano, Texas $713M AUM 16.55% 1-Year Est. Return
PCS
Personal CFO Solutions Chester, New Jersey $712M AUM 25.3% 1-Year Est. Return
ACGDR
Atmos Capital Gestao de Recursos Leblon - Rio De Janeiro, Brazil $714M AUM 35.97% 1-Year Est. Return
GEA
Glen Eagle Advisors Kingston, New Jersey $714M AUM 18.87% 1-Year Est. Return
ECM
EagleClaw Capital Management Boston, Massachusetts $714M AUM 24.24% 1-Year Est. Return

Tri Locum Partners's Q3 2024 Portfolio in Review

As of Q3 2024, Tri Locum Partners held 27 positions worth $417M, up 5.5% from $395M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Tri Locum Partners withdrew a net $16.8M in Q3 2024, closing 7 positions and reducing 6 holdings. Its most notable exit was Ascendis Pharma A/S, an estimated $31.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Tri Locum Partners opened a new position in Verona Pharma worth $17.1M.

  • Tri Locum Partners's largest Q3 2024 buy was Verona Pharma: 593,980 shares worth $17.1M.
  • Tri Locum Partners added most to Pfizer in Q3 2024, an estimated $33.1M increase.
  • Tri Locum Partners's biggest Q3 2024 reduction was Axsome Therapeutics, cutting an estimated $18.7M.
  • Tri Locum Partners fully exited Ascendis Pharma A/S in Q3 2024, selling an estimated $31.1M.
  • Tri Locum Partners's ten largest holdings make up 80% of its $417M portfolio in Q3 2024.
  • Tri Locum Partners opened 2 new positions and closed 7 in Q3 2024.
  • Tri Locum Partners's portfolio value rose 5.5% quarter-over-quarter to $417M.

Based on Tri Locum Partners's 13F filing for Q3 2024, filed 14 Nov 2024.